Polaris’ Amir Nashat pulls together a $60M launch round to back the birth of a new biotech building a drug development platform from scratch

Polaris Partners managing partner Amir Nashat has become a student of the role that biomolecular condensates play in shutting down or activating proteins. And he’s convinced that he’s found a door that opens on a long pathway to a new drug platform.